Q-omics provides the consensus-scored SNORD15A profile across patient tissues and cancer cell-line models. SNORD15A expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SNORD15A is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, SNORD15A RNA expression shows 6,906 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, HNSC, and UVM as cancer lineages where SNORD15A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORD15A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORD15A survival associations across molecular data types. SNORD15A RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORD15A RNA expression–survival associations across cancer types. High SNORD15A expression shows unfavorable associations in KIRC, OV, COAD and ACC, but favorable associations in UCS and THCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SNORD15A RNA expression.
This table summarizes SNORD15A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for SNORD15A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORD15A shows higher tumor expression in HNSC, COAD, BLCA, LUSC, BRCA and ESCA. The HNSC box plot shows higher SNORD15A RNA expression in tumor versus normal tissue (log2 FC = +0.304, t-test p = .002).
This table shows molecular features associated with SNORD15A in patient tissues and cancer cell lines. In patient samples, SNORD15A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
